Ellis Frazier, MD
Family Medicine · Piketon, OHNPI 1245228196
Payments from drug & device makers
Across 137 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$500
- Novo Nordisk$460
- Gilead$356
- AstraZeneca$339
- Viiv Healthcare Company$112
- Merck$100
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,80697%
- Education$743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $500 |
| Novo Nordisk | 23 | $460 |
| Gilead | 7 | $356 |
| AstraZeneca | 10 | $339 |
| Viiv Healthcare Company | 5 | $112 |
| Merck | 6 | $100 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| Lilly USA, LLC | 4 | $93 |
| Abbott | 3 | $58 |
| Pfizer | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 5 | $52 |
| Ironshore Pharmaceuticals Inc. | 1 | $50 |
| Exact Sciences | 3 | $49 |
| Novartis | 3 | $46 |
| GSK | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Grifols USA, LLC | 1 | $29 |
| Bayer | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,880 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 81 | $320,075 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 62 | $286,008 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 54 | $223,900 |
| JulucaDolutegravir/Rilpivirine | 40 | $135,499 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 32 | $119,205 |
| Enbrel SureclickEtanercept | 16 | $118,183 |
| DovatoDolutegravir Sodium/Lamivudine | 36 | $110,376 |
| MounjaroTirzepatide | 96 | $105,755 |
| OzempicSemaglutide | 99 | $101,661 |
| TrulicityDulaglutide | 77 | $84,836 |
| EliquisApixaban | 118 | $82,894 |
| PrezcobixDarunavir/Cobicistat | 31 | $62,425 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 20 | $57,494 |
| XareltoRivaroxaban | 74 | $52,384 |
| TivicayDolutegravir Sodium | 23 | $51,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $356 | $572,318148 claims |
| Viiv Healthcare CompanyJuluca, Triumeq, Dovato, Tivicay | $112 | $416,294131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $93 | $190,591173 claims |
| Novo NordiskOzempic, Rybelsus | $460 | $109,463123 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $21 | $101,264155 claims |
| PfizerEliquis, Abrysvo | $58 | $95,939161 claims |
| MerckDelstrigo, Janumet, Dulera | $100 | $74,73849 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $339 | $65,339115 claims |
| AbbVieLinzess | $500 | $25,54732 claims |
| NovartisEntresto | $46 | $23,37226 claims |
| GSKBreo Ellipta, Shingrix | $44 | $18,37960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Piketon
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.